Glaukos CEO Thomas William Burns Exercises Options, Then Sells $42.6 Million In Shares

Burns retained approximately $418.8 million in reported holdings after the trades under a pre-scheduled plan.

Share
Glaukos CEO Thomas William Burns Exercises Options, Then Sells $42.6 Million In Shares

Thomas William Burns, chairman and CEO of Glaukos, which develops eye therapies and devices, sold $42.6 million in shares Wednesday after exercising options, according to his SEC trading report filed Friday. He retained approximately $418.8 million in reported holdings, valued at Friday's closing price.

Options Bought, Shares Sold

Burns exercised options to buy 180,000 shares for $45.71 apiece Wednesday and sold the same number that day. The sales averaged $236.89 per share Wednesday; individual trades ranged from $232.17 to $246.03.

Both steps followed a pre-scheduled trading plan Burns adopted on August 20, 2026. The options covered by that plan expire on March 15, 2027.

The shares sold represented about 9% of Burns' reported stake before the filing. Glaukos stock was up about 111% this year as of Thursday's close, measured against its closing price at the end of 2025.

A $418.8 Million Remaining Holding

Burns' remaining reported holdings totaled 1,764,760 shares. Family trusts held 1,699,700, and he reported 65,060 directly.

The direct total included 48,673 restricted stock units—rights to receive shares—that were still unvested or awaiting delivery. Those units were included in the reported holdings used for the approximately $418.8 million valuation at Friday's $237.31 closing price.

Eye Treatments Beyond Drops

Glaukos develops and sells treatments for glaucoma, corneal disorders and retinal disease, emphasizing alternatives to eye drops. Its iStent implants help eye fluid drain, while iDose TR delivers glaucoma medication inside the eye. Its iLink therapies strengthen the cornea for conditions including keratoconus.

The iStent family, iDose TR and related accessories accounted for about 83% of 2025 net sales; iLink therapies supplied about 17%. U.S. customers generated 74% of net sales that year, compared with 26% internationally.

Glaukos sells primarily to eye surgeons working in ambulatory surgery centers, hospitals and private practices. It uses a direct sales team in the U.S.

Sources

More on Glaukos

All Glaukos (GKOS) coverage →